Rayburn West Financial Services LLC Takes $1.17 Million Position in Merck & Co., Inc. $MRK

Key Points

• Rayburn West Financial Services initiated a new position in Merck & Co. during the fourth quarter, buying 11,144 shares valued at about $1.17 million.
• Institutional ownership remains high, with 76.07% of Merck’s stock held by hedge funds and other institutional investors. Several firms also increased their stakes in the company during the quarter.
• Merck’s recent operating and pipeline news is generally positive: Keytruda helped drive first-quarter results above expectations, and the company plans to present extensive oncology data at ASCO 2026 while expanding KEYTRUDA collaborations.

Rayburn West Financial Services LLC purchased a new stake in Merck & Co., Inc. (NYSE:MRK - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 11,144 shares of the company's stock, valued at approximately $1,173,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Chesapeake Wealth Management increased its holdings in shares of Merck & Co., Inc. by 0.6% in the 4th quarter. Chesapeake Wealth Management now owns 14,740 shares of the company's stock valued at $1,552,000 after acquiring an additional 87 shares during the period. Westside Investment Management Inc. increased its holdings in shares of Merck & Co., Inc. by 3.1% in the 4th quarter. Westside Investment Management Inc. now owns 3,142 shares of the company's stock valued at $331,000 after acquiring an additional 93 shares during the period. Valued Wealth Advisors LLC increased its holdings in shares of Merck & Co., Inc. by 26.9% in the 4th quarter. Valued Wealth Advisors LLC now owns 444 shares of the company's stock valued at $47,000 after acquiring an additional 94 shares during the period. Payne Capital LLC increased its holdings in shares of Merck & Co., Inc. by 0.9% in the 4th quarter. Payne Capital LLC now owns 10,637 shares of the company's stock valued at $1,120,000 after acquiring an additional 97 shares during the period. Finally, Abound Wealth Management increased its holdings in shares of Merck & Co., Inc. by 6.8% in the 4th quarter. Abound Wealth Management now owns 1,554 shares of the company's stock valued at $164,000 after acquiring an additional 99 shares during the period. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analysts and market commentary highlighted that Keytruda drove Merck’s strong first-quarter sales, with revenue topping expectations and sales around $8 billion, reinforcing the drug’s importance to MRK’s 2026 growth outlook. Article Title
• Positive Sentiment: Merck said it will present new long-term oncology data and more than 100 abstracts at ASCO 2026, which could keep investor focus on the strength of its cancer portfolio and pipeline. Article Title
• Positive Sentiment: Merck broadened KEYTRUDA collaboration efforts with partners including Erasca and Inhibrx, signaling continued pipeline development around combination therapies as the company prepares for eventual patent-expiry pressure. Article Title
• Neutral Sentiment: One analyst reinstated Merck with a “Neutral” rating and a $125 price target, suggesting the stock may be fairly valued near current levels rather than clearly undervalued or overvalued. Article Title
• Neutral Sentiment: A valuation-focused article noted mixed recent share performance, including short-term weakness despite strong longer-term returns, which may be tempering enthusiasm even as fundamentals remain solid. Article Title

Merck & Co., Inc. Stock Up 1.1%

Shares of MRK stock opened at $113.57 on Thursday. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $125.14. The stock's fifty day moving average price is $116.31 and its 200 day moving average price is $109.01. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The company has a market cap of $280.49 billion, a price-to-earnings ratio of 31.99, a price-to-earnings-growth ratio of 2.53 and a beta of 0.18.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same period in the previous year, the business earned $2.22 EPS. The firm's revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, research analysts expect that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

MRK has been the topic of a number of analyst reports. Citigroup initiated coverage on Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a "neutral" rating and a $125.00 price target on the stock. Barclays started coverage on Merck & Co., Inc. in a research note on Friday, February 20th. They set an "overweight" rating and a $140.00 target price on the stock. Cantor Fitzgerald boosted their target price on Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 4th. Wells Fargo & Company dropped their target price on Merck & Co., Inc. from $150.00 to $145.00 and set an "overweight" rating on the stock in a research note on Friday, May 1st. Finally, UBS Group boosted their target price on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a "buy" rating in a research note on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $128.18.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.